R&D STRATEGY

R&D STRATEGY

Apaxen is focused on research and development of breakthrough therapeutics for the treatment of inflammatory and auto-immune diseases that depend on chronic activation of NLRP3 Inflammasomes.

By the use of an integrated medicinal chemistry and molecular biology driven approach, Apaxen identifies and develops small molecules that block NLRP3 Inflammasome construction and activation, via the neutralization of MIF (Macrophage Migration Inhibitory Factor). This platform approach allows for the development of a pipeline of novel therapeutics to treat a broad range of diseases that depend on NLRP3 inflammasome activity and high MIF expression. This includes many inflammatory and inflammaging related diseases, auto-immune diseases and many cancers.

Apaxen benefits from strategic collaborations with main academic research centers having translational expertise in NLRP3 Inflammasome biology and pulmonary arterial hypertension (PAH).